Try
Halozyme Therapeutics Inc. Common Stock
HALOUnited States
97 filed reports · 566 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
97 reports · Jun 2011 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 104 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 46 | 6,836 | Jun 2011 to Jun 2026 |
| Current · 8-KSEC EDGAR | 36 | 102 | Sep 2011 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 15 | 6,800 | Dec 2011 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 6, 2026 | 4 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 383 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 11, 2026 | 225 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 17, 2026 | 890 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 3, 2025 | 240 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 160 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 163 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 18, 2025 | 493 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 31, 2024 | 181 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 174 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 168 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 20, 2024 | 554 | Open |
Financial data
566 concepts · 13,738 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial551 concepts · 13,029 facts · Dec 2009 to Jul 2026
- Cash and cash equivalents at carrying value83 · Dec 2009 to Jun 2026
- Costs and expenses82 · Dec 2009 to Jun 2026
- Net income loss82 · Dec 2009 to Jun 2026
- Operating income loss82 · Dec 2009 to Jun 2026
- Revenue82 · Dec 2009 to Jun 2026
- Selling general and administrative expense82 · Dec 2009 to Jun 2026
- Depreciation depletion and amortization81 · Dec 2009 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities81 · Dec 2009 to Jun 2026
- Increase decrease in accounts receivable81 · Dec 2009 to Jun 2026
- Increase decrease in inventories81 · Dec 2009 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets81 · Dec 2009 to Jun 2026
- Payments to acquire property plant and equipment81 · Dec 2009 to Jun 2026
- Share based compensation81 · Dec 2009 to Jun 2026
- Research and development expense80 · Dec 2009 to Jun 2026
- Stockholders equity (US GAAP)80 · Dec 2009 to Jun 2026
- Accounts payable current78 · Dec 2010 to Jun 2026
- Accounts receivable net current78 · Dec 2010 to Jun 2026
- Accrued liabilities current78 · Dec 2010 to Jun 2026
- Additional paid in capital common stock78 · Dec 2010 to Jun 2026
- Assets78 · Dec 2010 to Jun 2026
- Assets current78 · Dec 2010 to Jun 2026
- Common stock par or stated value per share78 · Dec 2010 to Jun 2026
- Common stock shares authorized78 · Dec 2010 to Jun 2026
- Common stock shares issued78 · Dec 2010 to Jun 2026
Product9 concepts · 607 facts · Dec 2011 to Jun 2026
- Revenue515 · Dec 2011 to Jun 2026
- License and services revenue36 · Dec 2016 to Dec 2018
- Contract with customer performance obligation satisfied in previous period16 · Jun 2023 to Jun 2026
- Contract with customer liability revenue recognized15 · Mar 2019 to Dec 2023
- bulk rHuPH20 cost excluded from COGS 9 months ended 9/30/20149 · Dec 2012 to Dec 2014
- Cost of goods and services sold (US GAAP)5 · Mar 2019 to Dec 2019
- Manufacturing costs5 · Mar 2019 to Mar 2020
- License Fees And Event-Based4 · Jun 2019 to Mar 2021
- Sales discounts returns and allowances goods2 · Dec 2011 to Dec 2012
Guidance6 concepts · 102 facts · Nov 2011 to Aug 2026
- Revenue Guidance64 · Mar 2015 to Aug 2026
- EPS (Diluted) Guidance18 · Jan 2020 to Aug 2026
- Free Cash Flow Guidance12 · Nov 2011 to Aug 2015
- Operating Income Guidance4 · Feb 2021 to May 2021
- Net Income Guidance2 · May 2021
- Revenue Growth Guidance2 · May 2020
Segments
607 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis20 members · 480 facts
- License Fees And Event Based45 · Jun 2019 to Jun 2026
- Collaborative Agreements42 · Dec 2017 to Jun 2026
- Product42 · Dec 2017 to Jun 2026
- Royalty42 · Dec 2017 to Jun 2026
- Bulkr Hu PH2034 · Dec 2017 to Sep 2025
- Upfrontfees33 · Dec 2017 to Mar 2025
- Device Partnered Products27 · Dec 2020 to Jun 2026
- Proprietary Products Sales27 · Dec 2020 to Jun 2026
- Development Fees25 · Dec 2017 to Dec 2022
- Device Licensing And Development24 · Jun 2021 to Jun 2026
- Researchand Development Services23 · Dec 2017 to Dec 2023
- Event Based Development And Regulatory Milestone And Other Fees21 · Dec 2021 to Jun 2026
- Hylenex Recombinant21 · Dec 2017 to Mar 2022
- Salesbasedmilestone18 · Dec 2017 to Dec 2025
- ENHANZ Edrugproduct Member Domain16 · Dec 2017 to Mar 2021
- Upfront Fees13 · Dec 2022 to Jun 2026
- Bulk R Hu PH209 · Dec 2021 to Jun 2026
- Bulkr Hu PH20 And ENHANZE8 · Jun 2019 to Mar 2020
- Sales Based Milestone8 · Mar 2024 to Jun 2026
- ENHANZE Drug Product2 · Jun 2020 to Jun 2021
Product or serviceus-gaap:ProductOrServiceAxis18 members · 127 facts
- Bulkr Hu PH2016 · Dec 2012 to Mar 2019
- Hylenex Recombinant16 · Dec 2011 to Mar 2019
- Bulkr Hu PH20for Herceptin SC13 · Mar 2013 to Dec 2015
- Bulkr Hu PH20for Hy Qvia13 · Mar 2013 to Dec 2015
- Development Fees11 · Dec 2016 to Mar 2019
- ENHANZ Edrugproduct Member Domain11 · Dec 2016 to Mar 2019
- Researchand Development Services11 · Dec 2016 to Mar 2019
- Upfrontfees11 · Dec 2016 to Mar 2019
- Salesbasedmilestone9 · Dec 2016 to Dec 2018
- Bulkr Hu PH20priorperiod3 · Dec 2012 to Dec 2013
- Royalty3 · Mar 2018 to Mar 2019
- Bulkr Hu PH20 And ENHANZE2 · Mar 2019
- Collaborative Agreements2 · Mar 2018 to Mar 2019
- Product2 · Mar 2018 to Mar 2019
- AP Ifor Herceptin SC1 · Sep 2013
- AP Ifor Hy Qvia1 · Sep 2013
- Bulkr Hu PH20priorperiod21 · Dec 2012
- Bulkr Hu PH20priorperiod31 · Dec 2012
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary143 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary167 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes4 claims from 1 reports · Dec 2025
- Risk factors84 risks from 2 annual reports · 2024 to 2025
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.